RealFeedApp Gene editing therapy company shares increased by double digits
Stocks of gene editing therapy companies rose by double digits following data from the ESGCT Congress and new FDA draft guidance on personalized genome editing products.
- Field
- gene therapy
- What they did
- Shares of gene editing therapy companies surged due to data presented at the ESGCT Congress and new FDA draft guidance on personalized genome editing.
- Why it matters
- This regulatory framework aims to speed up approval processes for treating patients with rare genetic diseases by simplifying submission requirements.
#gene editing#fda#esgct#bla#rare genetic diseases
